Catalio Capital Management, LP
Catalio Capital Management, LP reported 39 US-listed holdings worth $532.1 million in its 13F for the quarter ended 30 June 2026, filed 2 September 2026. Its largest: Avalyn Pharma Inc. (10.4%), Johnson & Johnson (6.6%) and Gilead Sciences, Inc. (6.4%). Against the quarter before, it opened 11 positions, added to 15, trimmed 8 and sold out of 13.
Reported holdings$532.1M+11.2% on Q1 2026
Positions39-2 on Q1 2026
The largest ten56.7%of its reported holdings
Latest 13FQ2 2026filed 2 September 2026
OpenedAdded toTrimmed
The 14 largest of its 39 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +65.8% over the 6 quarters to 30 June 2026, against +27.4% for the S&P 500.
Its reported holdingsThe S&P 500
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Opened 11Added 15Held 5Trimmed 8Sold out 13
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 11
- Avalyn Pharma Inc. AVLN$55.2 million
- Johnson & Johnson JNJ$35.3 million
- Parabilis Medicines Inc. Com PBLS$22.6 million
- Protagonist Therapeutics, Inc. PTGX$13.1 million
- Axsome Therapeutics Inc. AXSM$10.6 million
- Kailera Therapeutics Inc. KLRA$10.3 million
- Odyssey Therapeutics, Inc. ODTX$8.6 million
- Ascendis Pharma A/s ASND$8.5 million
and 3 more in the table below
Added to 15
- Gilead Sciences, Inc. GILD+105,404 shares · +64%
- Septerna Inc. SEPN+241,792 shares · +82%
- Mineralys Therapeutics Inc. MLYS+209,681 shares · +48%
- Heartflow Inc. HTFL+179,467 shares · +44%
- Syndax Pharmaceuticals Inc. SNDX+172,028 shares · +16%
- Natera Inc Com NTRA+11,274 shares · +16%
- Corvus Pharmaceuticals Inc. CRVS+188,955 shares · +21%
- Disc Medicine Inc. IRON+36,406 shares · +30%
and 7 more in the table below
Trimmed 8
- Dianthus Therapeutics Inc. DNTH-527,367 shares · -94%
- Definium Therapeutics Inc. DFTX-475,312 shares · -46%
- Ultragenyx Pharmaceutical in RARE-534,545 shares · -63%
- Veradermics Inc MANE-127,726 shares · -74%
- Edwards Lifesciences Corp. EW-19,829 shares · -14%
- Dyne Therapeutics Inc. DYN-38,025 shares · -13%
- Bristol-Myers Squibb Co. BMY-7,766 shares · -2%
- Protara Therapeutics Inc. TARA-59,876 shares · -10%
Sold out of 13
- Ascendis Pharma A/s ASND$29.5 million last quarter
- Terns Pharmaceuticals Inc. TERN$21.6 million last quarter
- Soleno Therapeutics Inc. SLNO$19.3 million last quarter
- Boston Scientific Corp. BSX$18.8 million last quarter
- Cytokinetics Inc. CYTK$14.2 million last quarter
- Adaptive Biotechnologies Corporation ADPT$10.0 million last quarter
- Kalvista Pharmaceuticals Inc. KALV$8.6 million last quarter
- Uniqure NV QURE$8.0 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Avalyn Pharma Inc. AVLN | 1.7M | $55.2 million | 10.37% | new |
| Johnson & Johnson JNJ | 138.9K | $35.3 million | 6.63% | new |
| Gilead Sciences, Inc. GILD | 269.3K | $34.0 million | 6.39% | +105.4K |
| Bridgebio Pharma Inc. BBIO | 455.0K | $33.9 million | 6.37% | +23.0K |
| Syndax Pharmaceuticals Inc. SNDX | 1.2M | $26.6 million | 4.99% | +172.0K |
| Definium Therapeutics Inc. DFTX | 562.7K | $26.5 million | 4.97% | -475.3K |
| Bristol-Myers Squibb Co. BMY | 413.0K | $23.8 million | 4.47% | -7.8K |
| Parabilis Medicines Inc. Com PBLS | 824.0K | $22.6 million | 4.24% | new |
| Natera Inc Com NTRA | 82.2K | $22.3 million | 4.19% | +11.3K |
| Incyte Corp. INCY | 191.6K | $21.7 million | 4.08% | +9.5K |
| Septerna Inc. SEPN | 536.2K | $18.0 million | 3.37% | +241.8K |
| Mineralys Therapeutics Inc. MLYS | 648.7K | $17.5 million | 3.29% | +209.7K |
| Heartflow Inc. HTFL | 583.1K | $17.1 million | 3.21% | +179.5K |
| Corvus Pharmaceuticals Inc. CRVS | 1.1M | $16.1 million | 3.03% | +189.0K |
| Structure Therapeutics Inc. GPCR | 276.6K | $14.8 million | 2.79% | +21.2K |
| Protagonist Therapeutics, Inc. PTGX | 106.8K | $13.1 million | 2.46% | new |
| Disc Medicine Inc. IRON | 159.4K | $11.7 million | 2.19% | +36.4K |
| Edwards Lifesciences Corp. EW | 124.8K | $11.3 million | 2.12% | -19.8K |
| Axsome Therapeutics Inc. AXSM | 43.2K | $10.6 million | 1.99% | new |
| Ultragenyx Pharmaceutical in RARE | 316.3K | $10.6 million | 1.98% | -534.5K |
| Kailera Therapeutics Inc. KLRA | 468.8K | $10.3 million | 1.94% | new |
| Karyopharm Therapeutics Inc. KPTI | 940.9K | $9.2 million | 1.73% | +43.1K |
| Odyssey Therapeutics, Inc. ODTX | 457.8K | $8.6 million | 1.61% | new |
| Ascendis Pharma A/s ASND | 31.8K | $8.5 million | 1.59% | new |
| Kardigan Inc. KARD | 312.5K | $7.5 million | 1.40% | new |
| Eledon Pharmaceuticals Inc. ELDN | 1.7M | $6.7 million | 1.26% | +55.3K |
| 4D Molecular Therapeutics in FDMT | 471.3K | $6.3 million | 1.18% | new |
| Veradermics Inc MANE | 45.9K | $5.6 million | 1.06% | -127.7K |
| Dyne Therapeutics Inc. DYN | 244.9K | $5.4 million | 1.02% | -38.0K |
| Fractyl Health Inc. GUTS | 6.2M | $4.9 million | 0.92% | +676.9K |
| Immunocore Hldgs PLC IMCR | 148.0K | $4.7 million | 0.88% | +63.7K |
| Dianthus Therapeutics Inc. DNTH | 32.9K | $3.2 million | 0.60% | -527.4K |
| Bridgebio Oncology Therapeutics Ord BBOT | 318.4K | $2.4 million | 0.46% | new |
| Protara Therapeutics Inc. TARA | 520.1K | $2.0 million | 0.37% | -59.9K |
| Hyperfine Inc. HYPR | 1.3M | $1.8 million | 0.33% | no change |
| Atai Beckley NV ATAI | 196.9K | $1.0 million | 0.19% | no change |
| Metagenomi Inc. MGX | 529.0K | $629,502 | 0.12% | no change |
| Outset Med Inc. OM | 118.3K | $510,965 | 0.10% | no change |
| Sensei Biotherapeutics Inc. FTH | 14.7K | $367,950 | 0.07% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.